TENS of Auricular Vagal Nerve for Radiation Necrosis
Transcutaneous Auricular Vagal Nerve Stimulation for Treatment of Radiation Necrosis
This is a multi-center, randomized, blinded trial evaluating the effect of transcutaneous auricular vagal nerve stimulator (taVNS) on radiation necrosis-related cerebral edema. In this study, consenting and eligible patients will be assigned to one of two arms: treatment (Arm 1) or sham (Arm 2). Patients in both arms will have imaging performed and tissue and blood collected for assessment of changes in area of contrast enhancement and cerebral edema, inflammatory markers, and markers of blood-brain barrier permeability.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Amy Erickson
- 電話番号:804-828-9165
- メール:amy.erickson@vcuhealth.org
研究場所
-
-
Virginia
-
Richmond、Virginia、アメリカ、23298
- Virginia Commonwealth University
-
コンタクト:
- Amy Erickson
- 電話番号:804-828-9165
- メール:amy.erickson@vcuhealth.org
-
主任研究者:
- Ryan Cleary, MD
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- History of glioma or metastatic brain lesion previously treated with whole brain radiation, stereotactic radiation surgery, or fractionated radiation therapy
- Magnetic resonance imaging (MRI) findings consistent with possible radiation necrosis within 6 weeks prior to enrollment.
- Candidate for tissue biopsy and Laser Interstitial Thermal Therapy (LITT) ablation of the lesion
- At least 18 years of age
- If on corticosteroids, able to discontinue at least 5 days prior to start of transcutaneous auricular vagus nerve stimulation (taVNS) (Arm 1) or sham treatment (Arm 2). A stable physiologic dose of corticosteroids, if used as hormone replacement therapy, may be allowed upon discussion with the investigator. 6. Ability to understand and willingness to sign an institutional review board (IRB) approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.
Exclusion Criteria:
- New onset neurologic deficits secondary to radiation necrosis requiring initiation of dexamethasone therapy or other intervention prior to enrollment
- Currently receiving bevacizumab for treatment of radiation necrosis or has received bevacizumab < 6 weeks prior to study enrollment.
- Currently receiving any investigational agents for treatment of radiation necrosis or has participated in a study of an investigational agent for radiation necrosis within 3 weeks prior to study enrollment.
- History of cardiac conduction disorders or presence of implanted electronic devices
- Active Crohn's disease or other inflammatory bowel disease.
- Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
偽コンパレータ:シャム
|
TENS (transcutaneous electrical nerve stimulation) unit connected to an earpiece that fits into the concha of the ear, with no stimulation twice daily for 12 to 14 days prior to planned LITT ablation. |
|
実験的:経皮的耳介迷走神経刺激 (taVNS)
|
Transcutaneous auricular vagal nerve stimulation (taVNS) stimulation twice daily for 12 to 14 days prior to planned LITT ablation via TENS (transcutaneous electrical nerve stimulation) unit connected to an earpiece that fits into the concha of the ear. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Assess changes in the serum inflammatory marker Tumor Necrosis Factor (TNF)-alpha
時間枠:Baseline, 1 week, and 2 weeks following intervention
|
Percent change in serum inflammatory marker TNF-alpha utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, 1 week, and 2 weeks following intervention
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Assess changes in serum inflammatory marker Interleukin 12 (IL-12)
時間枠:Baseline, 1 week, and 2 weeks following intervention
|
Percent change in (IL-12) serum inflammatory marker utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, 1 week, and 2 weeks following intervention
|
|
Assess changes in serum inflammatory marker granulocyte-macrophage colony-stimulating factor (GMCSF)
時間枠:Baseline, 1 week, and 2 weeks following intervention
|
Percent change in serum inflammatory marker GMCSF utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, 1 week, and 2 weeks following intervention
|
|
Assess changes in serum inflammatory marker Interferon gamma (IFN gamma)
時間枠:Baseline, 1 week, and 2 weeks following intervention
|
Percent change in serum inflammatory marker IFN gamma utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, 1 week, and 2 weeks following intervention
|
|
Assess changes in serum inflammatory marker interleukin 1 beta (IL-1b)
時間枠:Baseline, 1 week, and 2 weeks following intervention
|
Percent change in serum inflammatory marker IL-1b utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, 1 week, and 2 weeks following intervention
|
|
Assess changes in serum inflammatory marker interleukin-10 (IL-10)
時間枠:Baseline, 1 week, and 2 weeks following intervention
|
Percent change in serum inflammatory marker IL-10 utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, 1 week, and 2 weeks following intervention
|
|
Assess changes in serum inflammatory marker interleukin 13 (IL-13)
時間枠:Baseline, 1 week, and 2 weeks following intervention
|
Percent change in serum inflammatory marker IL-13 utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, 1 week, and 2 weeks following intervention
|
|
Assess changes in serum inflammatory marker interleukin (IL-2)
時間枠:Baseline, 1 week, and 2 weeks following intervention
|
Percent change in serum inflammatory marker IL-2 utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, 1 week, and 2 weeks following intervention
|
|
Assess changes in serum inflammatory markers interleukin 17 (IL-17A)
時間枠:Baseline, 1 week, and 2 weeks following intervention
|
Percent change in serum inflammatory markers IL-17A utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, 1 week, and 2 weeks following intervention
|
|
Assess changes in serum inflammatory marker interleukin 4 (IL-4)
時間枠:Baseline, 1 week, and 2 weeks following intervention
|
Percent change in serum inflammatory marker IL-4 utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, 1 week, and 2 weeks following intervention
|
|
Assess changes in serum inflammatory marker interleukin 5 (IL-5)
時間枠:Baseline, 1 week, and 2 weeks following intervention
|
Percent change in serum inflammatory markers IL-5 utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, 1 week, and 2 weeks following intervention
|
|
Assess changes in serum inflammatory marker interleukin 6 (IL-6)
時間枠:Baseline, 1 week, and 2 weeks following intervention
|
Percent change in serum inflammatory markers IL-6 utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, 1 week, and 2 weeks following intervention
|
|
Assess changes in serum inflammatory marker interleukin 8 (IL-8)
時間枠:Baseline, 1 week, and 2 weeks following intervention
|
Percent change in serum inflammatory markers IL-8 utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, 1 week, and 2 weeks following intervention
|
|
Assess changes in biomarker Neurofilament light chain (NFL) of central nervous system (CNS) injury following treatment
時間枠:Baseline, and 2 weeks following intervention
|
Percent change of NFL marker of CNS inflammation utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, and 2 weeks following intervention
|
|
Assess changes in biomarker platelet-derived growth factor receptor-beta (PDGFR-beta) of central nervous system (CNS) injury following treatment
時間枠:Baseline, and 2 weeks following intervention
|
Percent change of marker PDGFR-beta of CNS inflammation utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, and 2 weeks following intervention
|
|
Assess changes in biomarker vascular endothelial growth factor (VEGF) of central nervous system (CNS) injury following treatment
時間枠:Baseline, and 2 weeks following intervention
|
Percent change of marker VEGF of CNS inflammation utilizing serum inflammatory marker analysis from collected blood samples |
Baseline, and 2 weeks following intervention
|
|
Assess changes in biomarkers of blood-brain barrier (BBB) permeability following treatment
時間枠:Baseline, and 2 weeks following intervention
|
Percent change of BBB permeability |
Baseline, and 2 weeks following intervention
|
|
Assess interval changes in radiation necrosis on MRI after treatment w taVNS
時間枠:Baseline, and 2 weeks following intervention
|
Percent changes in areas of contrast enhancement and perilesional T2-weighted fluid-attenuated inversion recovery (T2/FLAIR) Hypersensitivity on magnetic resonance imaging (MRI). On these images, areas with higher water content suck as edema, inflammation, or demyelination, appear brighter compared to surrounding tissue. |
Baseline, and 2 weeks following intervention
|
|
Assess interval changes in cerebral edema on MRI after treatment
時間枠:Baseline, and 2 weeks following intervention
|
Percent changes in areas of contrast enhancement and perilesional T2/FLAIR Hypersensitivity on MRI |
Baseline, and 2 weeks following intervention
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Ryan Cleary, MD、Virginia Commonwealth University
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。